Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice

Complement receptor 1-related gene/protein y (Crry) in rodents is a potent membrane complement regulator that inhibits complement C3 activation by both classical and alternative pathways. To clarify the role of complement in lupus nephritis, MRL/lpr mice were given Crry as a recombinant protein (Crry-Ig) from 12 to 24 wk of age. Control groups were given saline or normal mouse IgG. Sera and urine were collected biweekly. Only 1 of 20 (5%) Crry-Ig-treated mice developed renal failure (BUN > 50 mg/dl) compared with 18 of 38 (47.4%) mice in control groups (P = 0.001). BUN levels at 24 wk were reduced from 68.8 +/- 9.7 mg/dl in control groups to 38.5 +/- 3.9 mg/dl in the Crry-Ig-treated group (P < 0.01). Urinary albumin excretion at 24 wk was also significantly reduced from 5.3 +/- 1.4 mg/mg creatinine in the control groups to 0.5 +/- 0.2 mg/mg creatinine in the Crry-Ig-treated group (P < 0.05). Of the histologic data at 24 wk, there was a significant reduction in scores for glomerulosclerosis and C3d, IgG, IgG3, and IgA staining intensity in glomeruli in complement-inhibited animals. Crry-Ig-treated animals were also protected from vasculitic lesions. Although there was no effect on relevant autoimmune manifestations such as anti-double stranded DNA titers or cryoglobulin IgG3 levels, circulating immune complex levels were markedly higher in complement-inhibited animals. Thus, inhibition of complement activation with Crry-Ig significantly reduces renal disease in MRL/lpr lupus mice. The data support the strategy of using recombinant complement C3 inhibitors to treat human lupus nephritis.     

Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure

BACKGROUND: Acute renal failure (ARF) in sepsis occurs when the release of multiple inflammatory mediators is induced by bacterial endotoxins. C3 mRNA is markedly up-regulated in mouse kidney after exposure to lipopolysaccharide (LPS). We hypothesized that LPS could induce tubular synthesis and secretion of C3, leading to activation of the complement cascade and direct renal tubular injury. METHODS: ARF was induced in mice by intravenous injection of LPS and was confirmed by an acute rise in blood urea nitrogen (BUN) and histologically by acute tubular necrosis. Three separate strategies were used to investigate the role of the complement system in this model of ARF: (1) Crry-Ig, a recombinant protein containing the potent murine complement C3 activation inhibitor Crry was injected at the same time as LPS (N = 8). (2) LPS was injected into transgenic mice overexpressing Crry in glomeruli and tubules (N = 8), and (3) LPS was injected into C3-deficient mice (N = 5). RESULTS: Compared with unmanipulated mice, C3 staining by immunofluorescence (IF) microscopy in mice injected with LPS was greater in renal cortical tubular cells (IF score of 2. 1 +/- 0.1 vs. 1.4 +/- 0.2 in controls, P = 0.013), most prominently at the basolateral surface. LPS injection led to a 16- to 42-fold increase in urinary C3 excretion. Despite reduction or complete elimination of renal C3 with maneuvers suppressing complement activation, BUN values were not statistically different across all groups. In no experiment did BUN values correlate with the extent of C3 staining. CONCLUSION: Although LPS up-regulates renal C3 synthesis, resulting in basolateral tubular C3 deposition, this is not responsible for LPS-induced ARF in mice.     

Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure

Crry is a potent complement regulator in rodents that inhibits C3 convertases. In rats, intrarenal arterial injection of anti-glomerular endothelial cell (GEN) antibodies leads to complement-dependent microvascular injury and acute renal failure. In this study, a mouse variant of this model and the effects of complement inhibition were examined. Transgenic mice that overexpressed soluble Crry systemically and in their kidneys were studied. Anti-GEN IgG was injected intravenously into eight Crry transgenic mice and seven transgene-negative littermates (which were used as control animals). Thirty h after injection, blood urea nitrogen (BUN) levels were 30.3 +/- 4.4 and 114.8 +/- 23.5 mg/dl for transgene-positive and -negative animals, respectively (P = 0.012). Four of five transgene-negative animals with BUN levels of > 100 mg/dl were anuric; the remaining animal exhibited minimal albuminuria and no detectable urinary C3. In animals with renal failure, glomerular capillary collapse and tubular necrosis were observed. There was significant tubular staining for C3 in transgene-negative animals, with cellular and basal distributions, both of which were statistically greater than those in transgene-positive animals. Tubular cell C3 staining was strongly correlated with BUN values (r = 0.83, P < 0.001), as was C9 staining (r = 0.56, P = 0.037), suggesting that complement activation to the C5b-9 membrane attack complex had a casual role in renal failure. Thus, systemic injection of anti-GEN antibodies into mice leads to acute renal failure, with glomerular and tubular injury. Animals that overexpress soluble Crry in renal tubules and elsewhere are protected from the acute renal failure that occurs in this model, which ultimately seems to develop because of complement activation focused on tubules.     

Effects of Combined T- and B-Cell Deficiency on Murine Ischemia Reperfusion Injury

B and T cells have been implicated in the pathogenesis of renal ischemia reperfusion injury (IRI); however, it is unknown if B and T cells interact in early injury responses, as seen in adaptive immune responses. Recent evidence has shown that B-cell deficient and T-cell deficient mice are partially protected from renal IRI. Renal IRI was induced in recombinase activating gene (RAG)-1 deficient mice, which lack both B and T cells. RAG-1 deficient mice from two different background strains were not protected from renal IRI. Adoptive transfer of either B or T cells into RAG-1 deficient mice led to a significant protection of renal injury, which was independent of effects on neutrophil trafficking. Neutrophil depletion in RAG-1 deficient mice did not protect from IRI. While deficiency of either B or T cells reduced IRI, combined lack of both is not protective. These results demonstrate that complex interactions between B and T cells are likely occurring in kidney IRI.     

AMPK attenuates inflammation to reduce fibrosis induced by acute ischemia reperfusion injury in mice

Objective To observe the effect of adenosine monophosphate activated protein kinase (AMPK) on attenuating inflammation in fibrosis induced by acute ischemia reperfusion injury (IRI) in mice. Methods Forty eight male C57BL/6 mice were randomly divided into four groups: sham operation group (sham group), IRI group, AMPK inhibitor+IRI group (AMPK/IRI group) and normal saline+IRI group (NS/IRI group), 12 mice each group. The mice with renal IRI were occluded for 30 min through clipping bilateral renal pedicle, then released renal perfusion. Mice in sham group were performed the separation of renal pedicle without clipping. Mice in AMPK/IRI group and NS/IRI group were respectively intraperitoneal injected AMPK inhibitor and normal saline before IRI. At the 2 d after operation, 6 randomly-selected mice from each group were blooded by extraction eyeball to detect BUN and Scr. The renal histopathological changes were observed through HE staining. The mRNA expression of IL-1β, IL-6 and TNF-α was detected by real time PCR, and the level of AMPK phosphorylation was detected by Western blotting. At the 14 d after operation, Collagen 1 (COL1), α-SMA and fibronectin (FN) were detected by immunofluorescence and Western blotting in 6 remained mice from each group. The degree of kidney fibrosis was observed through sirus red staining. Results Compared with those in sham group, tubular interstitial damage was aggravated (P＜0.05), BUN and Scr were increased (P＜0.05), the mRNA expression of IL-1β, IL-6 and TNF-α was increased at the 2 d after operation (all P＜0.05), and the level of AMPK phosphorylation was activated in IRI group and NS/IRI group (all P＜0.05); the degree of kidney fibrosis and the expression of COL1, α-SMA and FN were increased obviously at the 14 d (all P＜0.05). Compared with those in IRI group, in AMPK/IRI group tubular interstitial damage was aggravated (P＜0.05), BUN and Scr were increased (all P＜0.05), the mRNA expression of IL-1β, IL-6 and TNF-α was increased at the 2 d (all P＜0.05), and the level of AMPK phosphorylation was decreased (P＜0.05). Moreover, the degree of kidney fibrosis and the expression of COL1, α-SMA and FN were increased obviously at the 14 d in AMPK/IRI group (all P＜0.05). Conclusions AMPK can ameliorate the acute renal ischemia reperfusion injury induce fibrosis in mice, and the mechanism may be related to the decrease of inflammatory reaction.     

纤维蛋白肽Bβ15～42对大鼠缺血再灌注损伤肾脏局部炎性反应的影响

目的 观察纤维蛋白肽Bβ15～42(the fibrin-derived peptide Bβ15-42,FgBβ15～42肽)对大鼠肾脏缺血再灌注损伤(IRI)后肾脏局部炎性反应的影响并探讨其机制.方法 将SD大鼠随机分成假手术组(Sham组)、IRI组、阴性治疗组和FgBβ15 ～ 42肽治疗组.Sham组:分离肾动脉后关闭腹腔;IRI组:采用双侧肾动脉夹闭的方法制作肾脏IRI模型;阴性治疗组:于肾脏再灌注后立即尾静脉注射随机肽段3.6 mg/kg; FgBβ15～42肽治疗组:于肾脏再灌注后立即尾静脉注射FgBβ15～ 42肽3.6 mg/kg.后3组按照再灌注24h、48 h分为两个亚组,Sham组与各亚组均为8只大鼠.常规生化法检测肾功能;HE、PAS染色观察肾脏组织学改变;免疫组化、实时荧光定量PCR法及Western印迹检测肾组织白细胞介素1β(IL-1β)、细胞间黏附分子1(ICAM-1)的mRNA及蛋白表达.结果 与Sham组相比,IRI组的Scr和BUN水平均显著增加(均P ＜0.05),肾小管及间质病理损伤显著,以再灌注48 h更为明显;与IRI组相比,FgBβ15～ 42肽治疗组Scr和BUN显著下降(均P＜0.05),小管间质损伤程度明显减轻(P＜0.05).与Sham组相比,IRI组IL-1β和ICA M-1的mRNA和蛋白水平于再灌注24h显著上升,48 h稍微下降,但仍维持在较高水平;FgBβ15～ 42肽治疗组大鼠肾组织IL-1β和ICAM-1的表达于再灌注24h、48 h显著低于同时间点的IRI组(均P＜0.05),但仍明显高于Sham组.上述各指标在阴性治疗组和IRI组之间的表达差异无统计学意义.结论 FgBβ15～42肽对肾脏IRI具有保护作用,其作用机制可能与其减少炎性因子IL-1β、黏附分子ICAM-1的表达有关.     

地塞米松预处理减轻肾缺血再灌注损伤

目的探讨地塞米松（dexamethasone,DEX）对小鼠肾缺血再灌注损伤的作用及其机制。方法建立小鼠肾缺血再灌注损伤模型。18只雄性C57BL／6小鼠随机分为3个组（n=6）,分别为假手术组（Sham）、肾缺血再灌注损伤模型组（IRI）和DEX预处理组。Sham和IRI组缺血前60min予生理盐水（腹腔注射）,DEX组缺血前60min给予DEX（4mg／kg）,IRI组和DEX组血管夹夹闭左侧肾蒂,置于32℃温箱后1h松开血管夹,去除右肾。Sham组操作同上,但不夹闭左侧肾蒂,再灌注24h后处死小鼠,收集血清和肾脏标本。PAS染色后观察肾脏病理形态学变化,PCR检测白细胞介素6（interleukin6,IL-6）、干扰素γ（interferonγ,IFN-γ）和肿瘤坏死因子（tumornecrosisfactorOt,TNF-a）Westernblotting检测pAkt和总的Akt。结果与Sham组相比,IRI组血清肌酐和血尿素氮明显升高。病理检查可见肾脏内肾小管上皮细胞明显肿胀坏死、蛋白管型形成明显,还可观察到炎症细胞浸润明显增加。PCR显示IL-6、IFN-γ和TNF-a mRNA水平明显上调,Westernblotting显示p-Akt蛋白表达量明显增加,但Akt蛋白表达量无明显差异。与IRI组相比,DEX治疗组血清肌酐、血尿素氮明显下降,肾小管上皮细胞肿胀坏死减轻、炎症细胞浸润减少,IL-6、IFN-γ和TNF-a表达降低,p-Akt表达减少,但Akt蛋白表达量无明显差异。结论DEX预处理可通过抑制Akt信号通路激活,从而抑制炎症反应,从而减轻肾缺血再灌注损伤。     

A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury

Complement is known to play a role in ischemia and reperfusion injury (IRI). A general paradigm is that complement is activated by self-reactive natural IgM antibodies (nAbs), after they engage postischemic neoepitopes. However, a role for nAbs in lung transplantation (LTx) has not been explored. Using mouse models of LTx, we investigated the role of two postischemic neoepitopes, modified annexin IV (B4) and a subset of phospholipids (C2), in LTx. Antibody deficient Rag1-/- recipient mice were protected from LTx IRI. Reconstitution with either B4 or C2nAb restored IRI, with C2 significantly more effective than B4 nAb. Based on these information, we developed/characterized a novel complement inhibitor composed of single-chain antibody (scFv) derived from the C2 nAb linked to Crry (C2scFv-Crry), a murine inhibitor of C3 activation. Using an allogeneic LTx, in which recipients contain a full nAb repertoire, C2scFv-Crry targeted to the LTx, inhibited IRI, and delayed acute rejection. Finally, we demonstrate the expression of the C2 neoepitope in human donor lungs, highlighting the translational potential of this approach.     

Crosstalk between Complement and Toll‐like Receptor Activation in Relation to Donor Brain Death and Renal Ischemia‐Reperfusion Injury

Two central pathways of innate immunity, complement and Toll‐like receptors (TLRs), play an important role in the pathogenesis of renal injury inherent to kidney transplantation. Recent findings indicate close crosstalk between complement and TLR signaling pathways. It is suggested that mitogen activated protein kinases (MAPKs) might be the key molecules linking both the complement and TLR pathways together. Complement and TLRs are important mediators of renal ischemia‐reperfusion injury (IRI). Besides IRI, complement C3 can also be upregulated and activated in the kidney before transplantation as a direct result of brain death (BD) in the donor. This local upregulation and activation of complement in the donor kidney has been proven to be detrimental for renal allograft outcome. Also TLR4 and several of its major ligands are upregulated by donor BD compared to living donors. Important and in line with the observations above, kidney transplant recipients have a benefit when receiving a kidney from a TLR4 Asp299Gly/Thr399Ile genotypic donor. The role of complement and TLRs and crosstalk between these two innate immune systems in relation to renal injury during donor BD and ischemia‐reperfusion are focus of this review. Future strategies to target complement and TLR activation in kidney transplantation are considered.     

Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response

Despite the introduction of novel and more targeted immunosuppressive drugs, the long‐term survival of kidney transplants has not improved satisfactorily. Early antigen‐independent intragraft inflammation plays a critical role in the initiation of the alloimmune response and impacts long‐term graft function. Complement activation is a key player both in ischemia/reperfusion injury (IRI) as well as in adaptive antigraft immune response after kidney transplantation. Since the alternative pathway (AP) amplifies complement activation regardless of the initiation pathways and renal IR injured cells undergo uncontrolled complement activation, we speculated whether selective blockade of AP could be a strategy for prolonging kidney graft survival. Here we showed that Balb/c kidneys transplanted in factor b deficient C57 mice underwent reduced IRI and diminished T cell–mediated rejection. In in vitro studies, we found that fb deficiency in T cells and dendritic cells conferred intrinsic impaired alloreactive/allostimulatory functions, respectively, both in direct and indirect pathways of alloantigen presentation. By administering anti‐fB antibody to C57 wt recipients in the early post Balb/c kidney transplant phases, we documented that inhibition of AP during both ischemia/reperfusion and early adaptive immune response is necessary for prolonging graft survival. These findings may have implication for the use of AP inhibitors in clinical kidney transplantation.     

Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury

Hydrogen sulfide (H₂S) can induce a reversible hypometabolic state, which could protect against hypoxia. In this study we investigated whether H₂S could protect livers from ischemia/reperfusion injury (IRI). Male C57BL/6 mice were subjected to partial hepatic IRI for 60 min. Animals received 0 (IRI) or 100 ppm H₂S (IRI + H₂S) from 30 min prior to ischemia until 5 min before reperfusion. Core body temperature was maintained at 37 °C. Animals were sacrificed after 1, 6 or 24 h. Hepatic ischemia caused extensive hepatic necrosis in the IRI animals which coincided with an increase in ALT and AST serum levels. Animals treated with H₂S showed attenuated serum ALT and AST levels and reduced necrotic lesions after 24 h. IRI animals had increased Bcl‐2 mRNA expression and increased active Caspase 3 protein, which were both significantly lower in H₂S treated animals. Increased TNFα and IL‐6 mRNA in the IRI livers was significantly attenuated by H₂S treatment, as was hepatic influx of Ly‐6G positive granulocytes. Hepatic superoxide production after ischemia was attenuated by H₂S treatment. In hepatic ischemia/reperfusion injury, gaseous H₂S treatment is highly protective, substantially reducing necrosis, apoptosis and inflammation. Gaseous H₂S is therefore a very promising treatment for reducing IRI during hepatic transplantation.     

钴原卟啉诱导血红素氧合酶-1高表达减轻大鼠肾脏缺血再灌注损伤

目的 探讨钴原卟啉(CoPP)诱导血红素氧合酶-1(HO-1)高表达对大鼠肾脏缺血再灌注损伤(IRI)的影响及其机理.方法 以Wistar大鼠为实验对象,CoPP组分别于左肾血流阻断前48 h和24 h腹腔注射CoPP 2.5 mg/kg,然后阻断左肾血流47 min,恢复左肾血流的同时切取大鼠右肾,采用免疫组织化学染色和免疫印迹法检测其HO-1的表达.在再灌注24 h后,处死大鼠,取其下腔静脉血和左肾,测定血肌酐(Cr)和尿素氮(BUN)浓度,观察肾组织学变化,检测肾组织中HO-1的表达.IRI组除不用CoPP处理外,其余同CoPP组.CoPP组和IRI组另有部分大鼠的血流阻断时间延长至80 min,恢复血流后不处死,观察14 d,记录其存活情况.结果 IRI组血清Cr及BUN分别为(134.37±24.26)μmol/L和(30.10±3.09)mmol/L,明显高于CoPP组的(48.92±12.92)μmol/L和(13.99±5.00)mmol/L(P＜0.05).IRI组肾小管细胞大片坏死,管型形成,与之相比,CoPP组肾小管坏死范围稍小,但肾小管病变范围仍较广泛,肾小管上皮细胞多处于水变性阶段,"缺血样"肾小球减少,管型形成较少.缺血前及再灌注24 h后,CoPP组的肾组织中HO-1均为高表达,主要位于肾间质的毛细血管处,IRI组再灌注24 h后也见肾组织中HO-1为高表达.术后14 d内,IRI组的6只大鼠中有4只死亡,而CoPP组的5只大鼠全部存活,两组大鼠存活率的差异有统计学意义(P＜0.05).结论 缺血前使用CoPP可减轻大鼠肾脏缺血再灌注损伤,该保护作用可能是通过CoPP诱导肾脏高表达HO-1来实现的.     

Development of a novel porcine ischemia/reperfusion model inducing different ischemia times in bilateral kidneys-effects of hydrogen gas inhalation

BackgroundAcute kidney injury and its central pathology, renal ischemia reperfusion injury (IRI), have been studied in many animal models. Although renal IRI has been induced in pig models in many ways, simultaneous bilateral ischemia or unilateral ischemia along with contralateral nephrectomy models only provide data on the renal response to a single ischemia time. Moreover, it has been reported that prolonged renal ischemia time in pigs for 120 min or more can cause irreversible renal damage and increase animal mortality.MethodsWe developed a model that induces prolonged ischemia time and subsequent reperfusion injury without threatening the lives of pigs by subjecting the left and right kidneys to ischemia for 120 and 60 min, respectively. Using this novel model, we investigated whether hydrogen gas inhalation could alleviate renal IRI.ResultsAll animals (n=4) survived until the end of the observation period of 3 months in this model. Evaluation of the left and right kidneys immediately before and after IRI could be performed separately by blood sampling from each renal vein and renal biopsy during surgery, although the results of peripheral blood sampling during the follow-up were the mixed results of bilateral kidneys. The release of degraded DNA from the kidneys immediately after IRI and subsequent renal fibrosis at 3 months increased in response to ischemia time. Although the effect of hydrogen gas on pathological findings was not obvious, the release of degraded DNA from the kidney, an acute marker of IRI, appeared to be suppressed.ConclusionsWe have developed a novel model in which IRI of different ischemia times is induced in the bilateral kidney that provides two-fold information and allows for safe long-term observation experiments in pigs. Using this model, hydrogen gas inhalation appeared to reduce acute renal IRI, although the effect was not statistically significant.     

木兰脂素对肾缺血再灌注损伤大鼠P-选择素表达的影响

目的：探讨木兰脂素对大鼠肾缺血再灌注损伤是否具有保护作用及其可能机制。方法：雄性SD大鼠45只,随机分为假手术组、对照组和治疗组。除假手术组外,各组按再灌注时间又分为4个亚组,每组5只。治疗组和对照组分别在再灌注开始前5min静脉注射木兰脂素2mg/kg和等量生理盐水。再灌注达相应时间点时,从各亚组大鼠取血备测血肌酐（Scr）、血尿素氮（BUN）,肾组织用于观察病理变化以及作免疫组化分析肾组织P-选择素表达情况。结果：对照组BUN、Scr较假手术组明显升高,治疗组BUN、Scr较相应时间点对照组明显降低（P〈0.05）;对照组的肾组织损伤较假手术组明显加重,而治疗组的肾组织损伤较对照组明显减轻;随着时间延长,对照组肾组织P-选择素阳性表达较假手术组显著增多,治疗组肾组织P-选择素阳性表达较对照组明显减少（P〈0.05）。结论：木兰脂素对大鼠肾缺血再灌注损伤具有一定的保护作用。     

外源性硫化氢在大鼠肾脏缺血再灌注损伤中的保护作用

目的 观察不同剂量外源性硫化氢(H2S)供体硫氢化钠对大鼠肾脏缺血再灌注损伤( IRI)的保护作用.方法 健康雄性Wistar大鼠28只随机分为4组,即假手术组( Sham)、肾缺血再灌注(IR)组、硫氢化钠(NaHS)高剂量组、硫氢化钠低剂量组.大鼠右肾切除后,以NaHS作为硫化氢的供体,NaHS高、低剂量组分别经左肾动脉插管,按照1.5 μmol/min、300 nmol/min的剂量连续15 min给药,假手术组及IR组给予同体积生理盐水.停药5 min 后,NaHS组和IR组用无损伤微动脉夹夹闭左侧肾蒂45 min后解除阻断,建立大鼠急性IRI模型,假手术组不夹闭左肾动脉,其他操作同模型组.于肾脏恢复血流24h时留取血和肾组织标本,检测血清尿素氮(BUN)、血肌酐(Scr);半定量分析肾脏病理损伤;检测肾组织H2S生成率;采用实时定量PCR法检测胱硫醚-β-合成酶(CBS)、胱硫醚-γ-裂解酶(CSE )mRNA表达.结果 与假手术组相比,IR组H2S生成率显著降低(P＜0.01);CBS、CSE mRNA表达显著下降(P＜0.01 );Scr、BUN显著升高(P＜0.01);肾脏病理表现为急性肾小管坏死,且最严重.与IR组相比,NaHS预处理组H2S生成率升高(P＜0.05);CBS、CSE mRNA表达升高(P＜0.01 );Scr、BUN降低(P＜0.01);病理损伤明显减轻.NaHS两个剂量组之间差异无统计学意义.结论 外源性H2S对大鼠IRI具有保护作用.     

Gpx1-Klk1转基因对肾缺血再灌注损伤保护作用的研究

目的 制备人谷胱甘肽过氧化物酶（Gpx1）、 组织激肽释放酶（Klk1）共转基因小鼠,在此基础上制作肾缺血再灌注损伤小鼠模型。观察转基因小鼠对缺血再灌注损伤的耐受能力。在体研究Gpx1-Klk1转基因对肾缺血再灌注的保护作用。 方法 应用基因工程技术制备pKsp-Gpx1-IRES-Klk1质粒,酶切后回收转基因片段并纯化,通过外源基因受精卵雄原核显微注射法制备Gpx1-Klk1共转基因小鼠。采用丝线悬吊控制法制备转基因小鼠肾缺血再灌注模型。设立C57BL野生型小鼠同法制备的肾缺血再灌注损伤为对照。在肾缺血再灌注实验前后,测定血尿素氮、血肌酐、肾组织中超氧化物歧化酶（SOD）、丙二醛（MDA）、总一氧化氮合酶（tNOS）及诱导型一氧化氮合酶（iNOS）。留取肾脏组织制备病理切片,观察Gpx1-Klk1转基因小鼠抗肾缺血再灌注损伤的能力。 结果 获得全长为6.585 kb的pKsp-Gpx1-IRES-Klk1重组质粒,并证明了该克隆的正确性。在转基因小鼠制备过程中,共获得525枚注射卵,移植成功率为81.0%,小鼠出生总数109只。经基因组DNA的PCR检测,确认10只为转基因阳性小鼠,阳性率为9.2%。Western印迹法检测证实了阳性转基因小鼠肾脏组织有Gpx1和Klk1蛋白强表达。转基因小鼠（实验组）和野生型小鼠（对照组）肾缺血再灌注损伤模型建立后,实验组血样中尿素氮及肌酐水平显著低于对照组（P < 0.01）;肾脏组织中SOD显著高于对照组 （P < 0.01）,MDA显著低于对照组（P < 0.01）;两组肾组织中tNOS较缺血再灌注前均显著升高,且实验组显著高于对照组（P = 0.025）,实验组肾组织中iNOS显著低于对照组（P < 0.01）。缺血再灌注后,实验组肾组织间质轻度水肿,肾小管上皮坏死细胞较少,对标本损伤程度采用半定量评分后显示,实验组损伤程度显著轻于对照组（1.58±1.05比3.95±0.80,P < 0.05）。 结论成功制备Gpx1-Klk1转基因小鼠。Gpx1-Klk1过表达对肾缺血再灌注损伤的保护作用。     

低氧诱导因子1α高表达对小鼠急性缺血性肾损伤的影响

目的 探讨低氧预处理诱导低氧诱导因子1α（HIF-1α）高表达对小鼠肾缺血再灌注损伤（IRI）的影响及其可能机制。 方法 雄性C57BL/6N小鼠35只，随机分为健康对照组、氯化钴（CoCl2）组和8%O2组，每组10只；预处理12 h后，以上3组各取5只，分为缺血再灌注（IR）组、CoCl2＋IR组、8%O2＋IR组；另设5只作为假手术对照组。采用夹闭双侧肾蒂30 min的方法建立肾缺血动物模型，观察CoCl2和8％O2预处理对小鼠IR 24 h后肾功能、肾组织病理和相关肾损伤指标的影响及与CoCl2和8％O2诱导HIF-1α及其保护性靶基因血红素氧化酶1（HO-1）表达之间的关系。 结果 CoCl2＋IR组小鼠的肾功能[BUN (35.2±12.2) mmol/L，Scr (34.0±9.7) μmol/L]和8%O2＋IR组小鼠的肾功能[BUN (31.8±9.1) mmol/L，Scr (41.6±10.6) μmol/L]均较IR组[BUN (65.8±2.6) mmol/L，Scr (229.5±11.2) μmol/L]显著改善（P < 0.01）；与此相一致，CoCl2＋IR组和8%O2＋IR组的病理学改变、细胞凋亡程度和波形蛋白的表达均明显低于IR组。另外，CoCl2组和8%O2组中HIF-1α及其靶基因HO-1的表达明显高于健康对照组。 结论 低氧预处理可上调体内HIF-1α表达，对小鼠IRI肾脏具有良好保护效果     

Anti‐LG3 Antibodies Aggravate Renal Ischemia–Reperfusion Injury and Long‐Term Renal Allograft Dysfunction

Pretransplant autoantibodies to LG3 and angiotensin II type 1 receptors (AT1R) are associated with acute rejection in kidney transplant recipients, whereas antivimentin autoantibodies participate in heart transplant rejection. Ischemia–reperfusion injury (IRI) can modify self‐antigenic targets. We hypothesized that ischemia–reperfusion creates permissive conditions for autoantibodies to interact with their antigenic targets and leads to enhanced renal damage and dysfunction. In 172 kidney transplant recipients, we found that pretransplant anti‐LG3 antibodies were associated with an increased risk of delayed graft function (DGF). Pretransplant anti‐LG3 antibodies are inversely associated with graft function at 1 year after transplantation in patients who experienced DGF, independent of rejection. Pretransplant anti‐AT1R and antivimentin were not associated with DGF or its functional outcome. In a model of renal IRI in mice, passive transfer of anti‐LG3 IgG led to enhanced dysfunction and microvascular injury compared with passive transfer with control IgG. Passive transfer of anti‐LG3 antibodies also favored intrarenal microvascular complement activation, microvascular rarefaction and fibrosis after IRI. Our results suggest that anti‐LG3 antibodies are novel aggravating factors for renal IRI. These results provide novel insights into the pathways that modulate the severity of renal injury at the time of transplantation and their impact on long‐term outcomes.